ALK and pancreatic neoplasm: Finally, clinical trials (NCT02227940, NCT01497392) using ALK and FGFR inhibitors have been approved for advanced pancreatic cancer, further providing a rationale for testing the above-mentioned inhibitors in preclinical mouse models of pancreatic cancer.